← All trials
NCT04722575
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 12, 2020
- Primary completion
- Mar 31, 2022
- Completion date
- Jun 30, 2027
- First posted
- Jan 25, 2021
- Last posted
- Jan 25, 2021
- Enrollment
- 88
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Fondazione Melanoma OnlusLead sponsor
- Clinical Research Technology S.r.l.Collaborator
- Fondazione Melanoma OnlusStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.